Evidence map›Paper›PMID 34640576›Full record

ArticleJournal of clinical medicine2021

The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030.

Marleen van Dijk, Sylvia M Brakenhoff, Cas J Isfordink, Wei-Han Cheng, Hans Blokzijl, Greet Boland, Anthonius S M Dofferhoff, Bart van Hoek, Cees van Nieuwkoop, Milan J Sonneveld and 3 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marleen van DijkDepartment of Gastroenterology and Hepatology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0001-9092-0481
Sylvia M BrakenhoffDepartment of Gastroenterology and Hepatology, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands.
Cas J IsfordinkDepartment of Gastroenterology and Hepatology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.
Wei-Han ChengHealth Economics and Outcomes Research, AbbVie Inc., North Chicago, IL 60064, USA.
Hans BlokzijlDepartment of Gastroenterology and Hepatology, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands.
Greet BolandDepartment of Medical Microbiology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-7670-9978
Anthonius S M DofferhoffDepartment of Internal Medicine, Canisius Wilhelmina Hospital, Radboud University Medical Centre, 6532 SZ Nijmegen, The Netherlands.
Bart van HoekDepartment of Gastroenterology and Hepatology, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands.ORCID 0000-0001-6527-764X
Cees van NieuwkoopDepartment of Internal Medicine, Haga Teaching Hospital, 2545 AA The Hague, The Netherlands.ORCID 0000-0003-0734-0844
Milan J SonneveldDepartment of Gastroenterology and Hepatology, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands.
Marc van der ValkDivision of Infectious Diseases, Department of Internal Medicine, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Joost P H DrenthDepartment of Gastroenterology and Hepatology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
Robert J de KnegtDepartment of Gastroenterology and Hepatology, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-0934-6975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Netherlands strives for hepatitis C virus (HCV) elimination, in accordance with the World Health Organization targets. An accurate estimate when HCV elimination will be reached is elusive. We have embarked on a nationwide HCV elimination project (CELINE) that allowed us to harvest detailed data on the Dutch HCV epidemic. This study aims to provide a well-supported timeline towards HCV elimination in The Netherlands.

methodsA previously published Markov model was used, adopting published data and unpublished CELINE project data. Two main scenarios were devised. In the Status Quo scenario, 2020 diagnosis and treatment levels remained constant in subsequent years. In the Gradual Decline scenario, an annual decrease of 10% in both diagnoses and treatments was implemented, starting in 2020. WHO incidence target was disregarded, due to low HCV incidence in The Netherlands (≤5 per 100,000).

resultsFollowing the Status Quo and Gradual Decline scenarios, The Netherlands would meet WHO's elimination targets by 2027 and 2032, respectively. From 2015 to 2030, liver-related mortality would be reduced by 97% in the Status Quo and 93% in the Gradual Decline scenario. Compared to the Status Quo scenario, the Gradual Decline scenario would result in 12 excess cases of decompensated cirrhosis, 18 excess cases of hepatocellular carcinoma, and 20 excess cases of liver-related death from 2020-2030.

conclusionsThe Netherlands is on track to reach HCV elimination by 2030. However, it is vital that HCV elimination remains high on the agenda to ensure adequate numbers of patients are being diagnosed and treated.

Indexed as

COVID-19eliminationHCVhepatitis Cmodel

Identifiers

PMID34640576
PMCPMC8509638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.